{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:27:18Z","timestamp":1786793238459,"version":"build-2736575974"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024589","name":"Institute of Advanced Study in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["IASST\/R&D\/LSD\/IHP-02\/2024-25\/677-684"],"award-info":[{"award-number":["IASST\/R&D\/LSD\/IHP-02\/2024-25\/677-684"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cyto.2024.156692","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:04:01Z","timestamp":1720512241000},"page":"156692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Breakthroughs in road mapping IL-35 mediated immunotherapy for type-1 and autoimmune diabetes mellitus"],"prefix":"10.1016","volume":"181","author":[{"given":"Ratul","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashis K.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asis","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cyto.2024.156692_b0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jir.2021.0147","article-title":"Interleukin-35: structure, function and its impact on immune-related diseases","volume":"41","author":"Ye","year":"2021","journal-title":"J. Interferon Cytokine Res."},{"issue":"24","key":"10.1016\/j.cyto.2024.156692_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415709","article-title":"Current insight into the role of IL-35 and its potential involvement in the pathogenesis and therapy of atopic dermatitis","volume":"23","author":"Zysk","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2024.156692_b0015","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.1073\/pnas.94.22.12041","article-title":"Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin","volume":"94","author":"Devergne","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cyto.2024.156692_b0020","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cyto.2018.05.019","article-title":"Emerging IL-12 family cytokines in the fight against fungal infections","volume":"111","author":"Thompson","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.cyto.2024.156692_b0025","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/13813455.2020.1837183","article-title":"Biomarkers in diabetic neuropathy","volume":"129","author":"Adki","year":"2023","journal-title":"Arch. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0030","doi-asserted-by":"crossref","DOI":"10.2174\/1573399817666210730094225","article-title":"Role of glycogen synthase kinase-3 in the etiology of type 2 diabetes mellitus: a review","volume":"18","author":"Bala","year":"2022","journal-title":"Curr. Diabetes Rev."},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0035","article-title":"Complications in diabetes mellitus: social determinants and trends","volume":"14","author":"Cuddapah","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.cyto.2024.156692_b0040","first-page":"217","article-title":"Epidemiology of type 2 diabetes: Indian scenario","volume":"125","author":"Mohan","year":"2007","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.cyto.2024.156692_b0045","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2009.726","article-title":"Diabetes in Asia: epidemiology, risk factors, and pathophysiology","volume":"301","author":"Chan","year":"2009","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.cyto.2024.156692_b0050","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0140-6736(09)60937-5","article-title":"Diabetes in Asia","volume":"375","author":"Ramachandran","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd2476","article-title":"Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials","volume":"8","author":"Calcutt","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5114\/ceji.2023.125043","article-title":"Interleukin 35: protective role and mechanism in type 1 diabetes","volume":"48","author":"Zhang","year":"2023","journal-title":"Cent. Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2024.156692_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2018.01.017","article-title":"Emerging role of IL-35 in inflammatory autoimmune diseases","volume":"17","author":"Su","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cyto.2024.156692_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312988","article-title":"Interleukin-35 prevents development of autoimmune diabetes possibly by maintaining the phenotype of regulatory B cells","volume":"22","author":"Luo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cyto.2024.156692_b0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/HYPERTENSIONAHA.109.145714","article-title":"Protein kinase C-dependent NAD(P)H oxidase activation induced by type 1 diabetes in renal medullary thick ascending limb","volume":"55","author":"Yang","year":"2010","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0080","first-page":"546","article-title":"Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian","volume":"20","author":"Chawla","year":"2016","journal-title":"J Endocrinol Metab."},{"issue":"12","key":"10.1016\/j.cyto.2024.156692_b0085","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2024.156692_b0090","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2024.156692_b0095","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.4049\/jimmunol.1100315","article-title":"Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance","volume":"186","author":"Chaturvedi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2024.156692_b0100","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.4049\/jimmunol.181.10.6898","article-title":"Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35","volume":"181","author":"Bardel","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2024.156692_b0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.cyto.2024.156692_b0110","article-title":"Expanding diversity in molecular structures and functions of the IL-6\/IL-12 heterodimeric cytokine family","volume":"4","author":"Hasegawa","year":"2016","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2024.156692_b0115","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the IL-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2024.156692_b0125","article-title":"IL-35 regulates the function of immune cells in tumor microenvironment","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/ATVBAHA.117.310626","article-title":"Il-35 (Interleukin-35) suppresses endothelial cell activation by inhibiting mitochondrial reactive oxygen species-mediated site-specific acetylation of H3K14 (Histone 3 Lysine 14)","volume":"38","author":"Li","year":"2018","journal-title":"Arteriosclerosis Thrombosis Vasc. Biol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0135","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/jcb.29441","article-title":"IL-35, a double-edged sword in cancer","volume":"121","author":"Yazdani","year":"2020","journal-title":"J. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.cyto.2024.156692_b0140","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.7150\/jca.29170","article-title":"Interleukin-35 as an emerging player in tumor microenvironment","volume":"10","author":"Xue","year":"2019","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.cyto.2024.156692_b0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/jir.2015.0015","article-title":"Interleukin-35: expanding its job profile","volume":"35","author":"Sawant","year":"2015","journal-title":"J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res."},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041149","article-title":"The role, involvement and function(s) of Interleukin-35 and Interleukin-37 in disease pathogenesis","volume":"19","author":"Bello","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050572","article-title":"Network pharmacology approach for medicinal plants: review and assessment","volume":"15","author":"Noor","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cyto.2024.156692_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152944","article-title":"LC-MS\/MS analysis and network pharmacology of Trigonella foenum-graecum - a plant from Ayurveda against hyperlipidemia and hyperglycemia with combination synergy","volume":"60","author":"Banerjee","year":"2019","journal-title":"Phytomedicine"},{"issue":"Suppl. 1","key":"10.1016\/j.cyto.2024.156692_b0165","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2024.156692_b0170","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2147\/DMSO.S275898","article-title":"Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications","volume":"13","author":"Wondmkun","year":"2020","journal-title":"Diabetes Metabolic Syndrome Obes."},{"issue":"17","key":"10.1016\/j.cyto.2024.156692_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2024.156692_b0180","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s00125-021-05415-5","article-title":"Defining the underlying defect in insulin action in type 2 diabetes","volume":"64","author":"Batista","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0185","first-page":"1","article-title":"Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus","volume":"9","author":"Burhans","year":"2018","journal-title":"Compreh. Physiol."},{"key":"10.1016\/j.cyto.2024.156692_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2014.00204","article-title":"Obesity-induced inflammation and insulin resistance","volume":"5","author":"Ota","year":"2014","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.cyto.2024.156692_b0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MED.0b013e3283514e13","article-title":"What causes the insulin resistance underlying obesity?","volume":"19","author":"Hardy","year":"2012","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"2","key":"10.1016\/j.cyto.2024.156692_b0200","first-page":"19","article-title":"Insulin and insulin resistance","volume":"26","author":"Wilcox","year":"2005","journal-title":"Clin. Biochemist. Rev."},{"issue":"5 Pt 1","key":"10.1016\/j.cyto.2024.156692_b0205","first-page":"E651","article-title":"Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting","volume":"256","author":"Boyle","year":"1989","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0210","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cyto.2024.156692_b0215","article-title":"Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025","volume":"10","author":"Lin","year":"2020","journal-title":"Sci. Rep."},{"issue":"44","key":"10.1016\/j.cyto.2024.156692_b0220","doi-asserted-by":"crossref","first-page":"31835","DOI":"10.1074\/jbc.M702481200","article-title":"Glucose regulates diacylglycerol intracellular levels and protein kinase C activity by modulating diacylglycerol kinase subcellular localization","volume":"282","author":"Miele","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.cyto.2024.156692_b0225","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0166-2236(89)90091-X","article-title":"The mechanism of protein kinase C activation","volume":"12","author":"Huang","year":"1989","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.cyto.2024.156692_b0230","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1083\/jcb.200203048","article-title":"Ca2+-controlled competitive diacylglycerol binding of protein kinase C isoenzymes in living cells","volume":"159","author":"Lenz","year":"2002","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.cyto.2024.156692_b0235","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1194\/jlr.R057984","article-title":"Phosphoinositide-specific phospholipase C in health and disease","volume":"56","author":"Cocco","year":"2015","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0240","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/imm.12510","article-title":"Protein kinase C in the immune system: from signalling to chromatin regulation","volume":"146","author":"Lim","year":"2015","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.cyto.2024.156692_b0245","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","article-title":"Activation of protein kinase C isoforms and its impact on diabetic complications","volume":"106","author":"Geraldes","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.cyto.2024.156692_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.716332","article-title":"Potential role of protein kinase C in the pathophysiology of diabetes-associated atherosclerosis","volume":"12","author":"Lien","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"13","key":"10.1016\/j.cyto.2024.156692_b0255","article-title":"The role of protein kinase C in diabetic microvascular complications","volume":"17","author":"Pan","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0260","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/08916930802587950","article-title":"AEB-071 has minimal impact on onset of autoimmune diabetes in NOD mice","volume":"42","author":"Merani","year":"2009","journal-title":"Autoimmunity"},{"issue":"12","key":"10.1016\/j.cyto.2024.156692_b0265","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/ng.249","article-title":"Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci","volume":"40","author":"Cooper","year":"2008","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.cyto.2024.156692_b0270","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.drudis.2014.05.008","article-title":"Protein kinase C inhibitors for immune disorders","volume":"19","author":"Altman","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"1\u20132","key":"10.1016\/j.cyto.2024.156692_b0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/19382014.2021.1890963","article-title":"Protein kinase C-\u03b8 knockout decreases serum IL-10 levels and inhibits insulin secretion from islet \u03b2 cells","volume":"13","author":"Hong","year":"2021","journal-title":"Islets"},{"issue":"11","key":"10.1016\/j.cyto.2024.156692_b0280","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1084\/jem.20020234","article-title":"Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells","volume":"197","author":"Pfeifhofer","year":"2003","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0285","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jmb.2005.10.043","article-title":"Differential roles of PKC-theta in the regulation of intracellular calcium concentration in primary T cells","volume":"355","author":"Manicassamy","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.cyto.2024.156692_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00530","article-title":"PKC-theta in regulatory and effector T-cell functions","volume":"6","author":"Brezar","year":"2015","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0295","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00125-003-1089-5","article-title":"The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure","volume":"46","author":"Roep","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.cyto.2024.156692_b0300","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0305","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2796.1993.tb00761.x","article-title":"Diacylglycerol\/protein kinase C signalling: a mechanism for insulin resistance?","volume":"234","author":"Shmueli","year":"1993","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0310","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4239\/wjd.v15.i3.572","article-title":"Regulatory role of peroxynitrite in advanced glycation end products mediated diabetic cardiovascular complications","volume":"15","author":"Bala","year":"2024","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0315","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/biom5010194","article-title":"Advanced glycation end products and oxidative stress in type 2 diabetes mellitus","volume":"5","author":"Nowotny","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2024.156692_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10050727","article-title":"Diabetic complications and oxidative stress: a 20-year voyage back in time and back to the future","volume":"10","author":"Iacobini","year":"2021","journal-title":"Antioxidants"},{"issue":"9","key":"10.1016\/j.cyto.2024.156692_b0325","doi-asserted-by":"crossref","first-page":"10697","DOI":"10.3390\/ijms130910697","article-title":"Cell signaling through protein kinase C oxidation and activation","volume":"13","author":"Cosentino-Gomes","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2024.156692_b0330","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopha.2018.02.105","article-title":"Involvement of growth factors in diabetes mellitus and its complications: a general review","volume":"101","author":"Shi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cyto.2024.156692_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00798","article-title":"NF-\u03ba\u03b2: a potential target in the management of vascular complications of diabetes","volume":"8","author":"Suryavanshi","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2024.156692_b0340","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cotox.2017.11.002","article-title":"NF-\u03baB in oxidative stress","volume":"7","author":"Lingappan","year":"2018","journal-title":"Curr. Opin. Toxicol."},{"issue":"6","key":"10.1016\/j.cyto.2024.156692_b0345","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","article-title":"Inflammatory cytokines in vascular dysfunction and vascular disease","volume":"78","author":"Sprague","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cyto.2024.156692_b0350","article-title":"Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DMBMJ","volume":"8","author":"Sartore","year":"2020","journal-title":"Open Diabetes Res. Care"},{"issue":"Pt 1","key":"10.1016\/j.cyto.2024.156692_b0355","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/BJ20040307","article-title":"Fructosamine 3-kinase-related protein and deglycation in human erythrocytes","volume":"382","author":"Collard","year":"2004","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010883","article-title":"Alphahydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population","volume":"5","author":"Gall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2024.156692_b0365","doi-asserted-by":"crossref","DOI":"10.1186\/1476-9255-5-17","article-title":"Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines\u2019 unexpected therapeutic properties","volume":"5","author":"Cunningham","year":"2008","journal-title":"J. Inflamm. (Lond.)"},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0370","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/193229681300700112","article-title":"A novel fasting blood test for insulin resistance and prediabetes","volume":"7","author":"Cobb","year":"2013","journal-title":"J. Diabetes Sci. Technol."},{"issue":"10","key":"10.1016\/j.cyto.2024.156692_b0375","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/DMSO.S100074","article-title":"Novel biomarkers for prediabetes, diabetes, and associated complications","volume":"14","author":"Dorcely","year":"2017","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"2","key":"10.1016\/j.cyto.2024.156692_b0380","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2337\/db12-0244","article-title":"PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110\u03b1 to the Golgi apparatus","volume":"62","author":"Wang","year":"2013","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0385","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2337\/diacare.29.04.06.dc05-1938","article-title":"Alpha2-Heremans-Schmid glycoprotein\/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans","volume":"29","author":"Stefan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2024.156692_b0390","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jad.2020.12.135","article-title":"Effects of Alpha-2-HS-glycoprotein on cognitive and emotional assessment in prediabetic and diabetic subjects","volume":"282","author":"Mancuso","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0395","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.cyto.2024.156692_b0400","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/db10-0796","article-title":"Interleukin-6 enhances glucosestimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway","volume":"60","author":"Suzuki","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2024.156692_b0405","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0083-6729(08)00621-3","article-title":"Interleukin-6 and insulin resistance","volume":"80","author":"Kim","year":"2009","journal-title":"Vitam. Horm."},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0410","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2337\/diacare.26.5.1439","article-title":"Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT\/EDIC cohort","volume":"26","author":"Klein","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.cyto.2024.156692_b0415","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4172\/jpb.1000139","article-title":"SERPINE 1 links obesity and diabetes: a pilot study","volume":"3","author":"Kaur","year":"2010","journal-title":"J. Proteomics Bioinform."},{"issue":"10","key":"10.1016\/j.cyto.2024.156692_b0420","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.2337\/diabetes.54.10.2932","article-title":"Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA\/KORA Augsburg Study, 1984\u20132002","volume":"54","author":"Thorand","year":"2005","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.cyto.2024.156692_b0425","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1210\/en.2011-1691","article-title":"Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes","volume":"152","author":"Donath","year":"2011","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0430","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0006-291X(68)90430-0","article-title":"Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group","volume":"32","author":"Bookchin","year":"1968","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.cyto.2024.156692_b0435","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00125-011-2162-0","article-title":"No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population","volume":"54","author":"Pfister","year":"2011","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0440","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/db09-1216","article-title":"Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT\/EDIC: comparison of adults and adolescents","volume":"59","author":"White","year":"2010","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.cyto.2024.156692_b0445","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2024.156692_b0450","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.7992","article-title":"A bibliometric analysis of IL-35 research from 2009 to 2018","volume":"7","author":"Cai","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.cyto.2024.156692_b0455","doi-asserted-by":"crossref","DOI":"10.1186\/s12950-019-0217-z","article-title":"IL-35 alleviates inflammation progression in a rat model of diabetic neuropathic pain via inhibition of JNK signaling","volume":"16","author":"Jiang","year":"2019","journal-title":"J. Inflamm."},{"key":"10.1016\/j.cyto.2024.156692_b0460","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc16-2121","article-title":"Increased interleukin-35 levels in patients with type 1 diabetes with remaining c-peptide","volume":"40","author":"Espes","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2024.156692_b0465","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/cei.13289","article-title":"Cellular immunological changes in patients with LADA are a mixture of those seen in patients with type 1 and type 2 diabetes","volume":"197","author":"Singh","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2024.156692_b0470","doi-asserted-by":"crossref","first-page":"258","DOI":"10.5114\/aoms.2020.101510","article-title":"Decreased interleukin-35 levels and CD4+EBI3+ T cells in patients with type 1 diabetes and the effects of the antibody against CD20 (rituximab)","volume":"17","author":"Ouyang","year":"2021","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.cyto.2024.156692_b0475","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.2337\/db10-1643","article-title":"Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta cell death","volume":"60","author":"Arif","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2024.156692_b0480","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.4049\/jimmunol.1000788","article-title":"IL-17 immunity in human type 1, diabetes","volume":"185","author":"Honkanen","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2024.156692_b0485","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cellsig.2013.11.031","article-title":"High glucose driven expression of proinflammatory cytokine and chemokine genes in lymphocytes: molecular mechanisms of IL-17 family gene expression","volume":"26","author":"Kumar","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cyto.2024.156692_b0490","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9051426","article-title":"Experimental diabetes mellitus in different animal models","volume":"2016","author":"Al-Awar","year":"2016","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.cyto.2024.156692_b0495","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00125-013-2935-8","article-title":"Double deficiency in IL-17 and IFN-c signalling significantly suppresses the development of diabetes in the NOD mouse","volume":"56","author":"Kuriya","year":"2013","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0500","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1535370220956943","article-title":"IL-17A is involved in diabetic inflammatory pathogenesis by its receptor IL-17RA","volume":"246","author":"Qiu","year":"2021","journal-title":"Exp. Biol. Med. (Maywood)."},{"key":"10.1016\/j.cyto.2024.156692_b0505","article-title":"Interleukin-35 prevents the elevation of the M1\/M2 ratio of macrophages in experimental type 1 diabetes","volume":"23","author":"Luo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0510","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/eji.201646493","article-title":"\u03b2-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice","volume":"47","author":"Manzoor","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0515","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jaci.2018.06.041","article-title":"Role of IL-35 in sublingual allergen immunotherapy","volume":"143","author":"Shamji","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0520","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.1080\/21655979.2022.2080367","article-title":"Interleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative diabetic retinopathy","volume":"13","author":"Yan","year":"2022","journal-title":"Bioengineered"},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0525","article-title":"Effect of interleukin (IL)-35 on IL-17 expression and production by human CD4+ T cells","volume":"15","author":"Okada","year":"2017","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0530","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1122","article-title":"Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets","volume":"9","author":"Lu","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0535","first-page":"295","article-title":"Serum levels of interleukin-23 and 35 in patients with and without type 2 diabetes mellitus and chronic periodontitis","volume":"10","author":"Maboudi","year":"2019","journal-title":"Caspian J. Intern. Med."},{"issue":"4","key":"10.1016\/j.cyto.2024.156692_b0540","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/eji.201444726","article-title":"TGF-\u03b2 converts Th1 cells into Th17 cells through stimulation of Runx1 expression","volume":"45","author":"Liu","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2024.156692_b0545","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/eji.200737810","article-title":"IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells","volume":"37","author":"Niedbala","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0550","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/eji.201646493","article-title":"\u03b2-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice","volume":"47","author":"Manzoor","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"685","key":"10.1016\/j.cyto.2024.156692_b0555","article-title":"IL-35 promotes microglial M2 polarization in a rat model of diabetic neuropathic pain","volume":"30","author":"Jiang","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"issue":"15","key":"10.1016\/j.cyto.2024.156692_b0560","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158156","article-title":"Photoreceptor cells constitutively express IL-35 and promote ocular immune privilege","volume":"23","author":"Yu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cyto.2024.156692_b0565","doi-asserted-by":"crossref","first-page":"651","DOI":"10.21037\/tp-22-100","article-title":"Interleukin-35 exhibits protective effects in a rat model of hypoxic-ischemic encephalopathy through the inhibition of microglia-mediated inflammation","volume":"11","author":"Liu","year":"2022","journal-title":"Transl. Pediatr."},{"key":"10.1016\/j.cyto.2024.156692_b0570","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/DMSO.S294742","article-title":"Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus","volume":"14","author":"Penaforte-Saboia","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.cyto.2024.156692_b0575","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcb.26174","article-title":"Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus","volume":"119","author":"Akash","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0580","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imm.13044","article-title":"Interleukin-35 in immune-related diseases: protection or destruction","volume":"157","author":"Zhang","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2024.156692_b0585","article-title":"Interleukin-35 administration counteracts established murine type 1 diabetes \u2013 possible involvement of regulatory T cells","volume":"5","author":"Singh","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0590","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156692_b0595","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13030422","article-title":"Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized medicine","volume":"13","author":"Popoviciu","year":"2023","journal-title":"J. Pers. Med."},{"issue":"8","key":"10.1016\/j.cyto.2024.156692_b0600","article-title":"Advances in the management of diabetes mellitus: a focus on personalized medicine","volume":"15","author":"Sugandh","year":"2023","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.cyto.2024.156692_b0605","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2337\/dc09-0373","article-title":"Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside","volume":"32","author":"Bresson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2024.156692_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2022.127040","article-title":"Antigen-specific immunotherapies in type 1 diabetes","volume":"73","author":"Zhang","year":"2022","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"8","key":"10.1016\/j.cyto.2024.156692_b0615","article-title":"T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes","volume":"5","author":"Burrack","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"11","key":"10.1016\/j.cyto.2024.156692_b0620","article-title":"Role of adiponectin and tumor necrosis factor-alpha in the pathogenesis and evolution of type 1 diabetes mellitus in children and adolescents","volume":"10","author":"Szabo","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.cyto.2024.156692_b0625","doi-asserted-by":"crossref","first-page":"50","DOI":"10.15420\/ecr.2018.33.1","article-title":"The role of inflammation in diabetes: current concepts and future perspectives","volume":"14","author":"Tsalamandris","year":"2019","journal-title":"Eur. Cardiol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:18:21Z","timestamp":1786792701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":125,"alternative-id":["S1043466624001959"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156692","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breakthroughs in road mapping IL-35 mediated immunotherapy for type-1 and autoimmune diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156692"}}